• Heterogeneity
• Resistance
• Animal Models

TECHNOLOGIES EMPLOYED IN NOVEL TARGETED THERAPEUTICS IN PDAC

MAJOR MOLECULAR TARGETS/PATHWAYS IMPLICATED IN PDAC

• Apoptosis Induction/Enhancement
• AEG35156/GEM640
• Imexon
• Lestaurtinib
• LY2181308
• MPC-6827
• RP101
• Arachidonic Acid Pathway Ihibitors
• Celecoxib
• LY293111
• Aurora Kinase Modulators
• MP235
• R763
• VX-680
• Epidermal Growth Factor Receptor (EGFr) Inhibitors
• Cetuximab
• EKB-569
• Erlotinib
• Gefitinib
• Matuzumab
• Panitumumab
• Farnesyl Transferase Inhibitors (FTI)
• Lonafarnib
• Tipifarnib
• Hedgehog Pathway Signaling Inhibitors
• Cyclopamine
• HhAntag
• Mammalian Target of Rapamycin (mTOR) Signaling Pathway Modulators
• AP23573
• Everolimus
• Temsirolimus
• Mammalian Target of Rapamycin (mTOR) Signaling Pathway Modulators
• AGRO1000
• AP12009
• ARRY-142886
• ARQ 501
• BMS-354825
• Bortezomib
• CC-401
• GTI 2040
• LY900003
• PDO325901
• Perifosine
• RAV12
• SDX-102

Exhibit 1 - Novel Targeted Theraputics Evaluated Either Clinically or Preclinically for the Treatment of Pancreatic Cancer

Exhibit 2 - Selected Putative Targets of Novel Anticancer Agents in Development for Pancreatic Cancer

Exhibit 3 - Ongoing Randomized Combination Clinical Trials of Cetuximab in PDAC